Actively Recruiting
Evaluating Tislelizumab, an Anti-PD-1 Antibody, as Monotherapy for Previously Treated MSI-H or dMMR Locally Advanced or Metastatic Solid Tumors in a Single-Arm Phase 2 Study
Led by BeiGene · Updated on 2026-10-26
200
Participants Needed
29
Research Sites
43 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Tislelizumab, an anti-PD-1 monoclonal antibody, in adults with previously treated locally advanced unresectable or metastatic solid tumors that have microsatellite instability-high MSI-H or mismatch repair deficient dMMR characteristics. This Phase 2, single-arm, multi-center, open-label study aims to assess the efficacy and safety of this immunotherapy in this specific cancer population. Participants will receive Tislelizumab as monotherapy. The study does not include a comparison group or placebo. Treatment details such as dosing schedules are not provided in the summary, but participants will be monitored for treatment response and safety over a period of up to two years. Throughout the study, participants will have measurable disease lesions assessed by independent and investigator review according to standardized criteria. Researchers will evaluate outcomes including objective response rate, duration and time to response, progression-free survival, disease control rate, overall survival, and safety based on adverse event reporting. The study duration includes up to two years of follow-up for these measurements.
CONDITIONS
Brief Title
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Research Team
B
BeiGene
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here